CN109528746A - Application of New Zealand's Isoorientin in the drug of preparation prevention and treatment senile dementia - Google Patents
Application of New Zealand's Isoorientin in the drug of preparation prevention and treatment senile dementia Download PDFInfo
- Publication number
- CN109528746A CN109528746A CN201910024767.0A CN201910024767A CN109528746A CN 109528746 A CN109528746 A CN 109528746A CN 201910024767 A CN201910024767 A CN 201910024767A CN 109528746 A CN109528746 A CN 109528746A
- Authority
- CN
- China
- Prior art keywords
- isoorientin
- new zealand
- senile dementia
- drug
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses application of New Zealand's Isoorientin in the drug of preparation prevention and treatment senile dementia.Senile dementia is a kind of using the retrogression pathological changes of central nervous system primary, progressive as the disease of main feature, and clinical manifestation is cognition and the irreversibility deterioration of memory function, and the A β for being primarily due to intracerebral over-deposit causes to damage to neuron.It is a discovery of the invention that New Zealand's Isoorientin can protect neural cell injury caused by A β, thus have exploitation at the prospect of anti senile dementia drug.
Description
Technical field
The invention belongs to field of medicaments, are related to the new application of known compound, and in particular to prepared by New Zealand's Isoorientin
Prevent and treat the application in the drug of senile dementia.
Background technique
Alzheimer's disease (Alzheimer ' s disease, AD) is also known as senile dementia, is one kind with progressive intelligence
The disease that degeneration and neuron loss are characterized.The over-65s old man of the whole world about 5-10% suffers from the disease at present, there are about
35000000 patients.Life cycle of the Disease after making a definite diagnosis only has 3 to 9 years, oneself is through becoming after cardiovascular and cerebrovascular disease and cancer
The third-largest killer of senior health and fitness is threatened later.AD is a kind of with central nervous system primary, the degenerative disease of progressive
Become the disease of main feature, clinical manifestation is cognition and the irreversibility deterioration of memory function, and major pathogenetic factor is intracerebral
The damage of A β (amyloid beta) neuron of over-deposit.It is many about the etiology and pathology research of AD in recent years, now compare
Generally acknowledged pathological characteristics, which are A β, causes central nervous system in the neurotoxicity that the senile plaque that intracerebral over-deposit is formed generates
Cholinergic neuron mortality, lose etc..Therefore inhibit the deposition of A β or mitigate damage of the A β to neuronal cell
It has become a hot topic of research and one of the Main way of drug development.
New Zealand's Isoorientin is a kind of flavone c-glycoside class natural products, there is no New Zealand's Isoorientin silly with anti-ageing year at present
The report of slow-witted effect.
Summary of the invention
The purpose of the present invention is to provide application of New Zealand's Isoorientin in the drug of preparation prevention and treatment senile dementia.
Above-mentioned purpose of the invention is realized by following technical solution:
Application of New Zealand's Isoorientin in the drug of preparation prevention and treatment senile dementia.
Application of the pharmaceutically acceptable salt of New Zealand's Isoorientin in the drug of preparation prevention and treatment senile dementia.
It is a kind of prevent and treat senile dementia pharmaceutical preparation, using New Zealand's Isoorientin or its pharmaceutically acceptable salt as drug
Pharmaceutically acceptable preparation formulation is made in active constituent.
Preferably, the preparation formulation is tablet, capsule, injection or oral solution.
The utility model has the advantages that it is main that senile dementia, which is a kind of retrogression pathological changes with central nervous system primary, progressive,
The disease of feature, clinical manifestation are cognition and the irreversibility deterioration of memory function, are primarily due to the A β couple of intracerebral over-deposit
Neuron causes to damage.It is a discovery of the invention that New Zealand's Isoorientin can protect neural cell injury caused by A β, thus has and open
Send out into the prospect of anti senile dementia drug.
Specific embodiment
One, experimental material
Aβ25-35Purchased from Beijing Bo Aosen Bioisystech Co., Ltd；Dimethyl sulfoxide (DMSO) is raw purchased from Shanghai Mike woods
Change Science and Technology Ltd.；Thiazolyl blue (MTT) is purchased from Dalian U.S. logical sequence Technology Co., Ltd.；New Zealand's Isoorientin is general purchased from Chengdu
Fei De Bioisystech Co., Ltd；Fetal calf serum is purchased from the biotech inc Zhejiang Tian Hang；RPMI-1640 culture medium
Purchased from Hyclone company.
Condensed state A β25-35Preparation: by 1mg A β25-35It is first dissolved in appropriate sterile dd H2In O, it is raw to add medical aseptic
Reason salt water makes A β25-35Final concentration of 1mM, 37 DEG C of water-baths are incubated for 7d.
Two, experimental method
1, cell culture
The rat neurogliocytoma cells C6 cell strain for being stored in liquid nitrogen frozen is taken out, is immediately placed in 37 DEG C of water-baths and vibrates
It after melting to cell, is transferred in the centrifuge tube that culture medium has been added, 5min is centrifuged with 1000rpm, discards supernatant liquid, be added a small amount of
Culture medium and gently pressure-vaccum is uniform, culture medium are containing 10% fetal calf serum, 1% dual anti-RPMI-1640 culture medium, by cell
Suspension moves into culture dish, in 37 DEG C, 5%CO2, cultivate under the conditions of saturated humidity.
2, the preparation of cell model
It is 2.0 × 10 that concentration, which is made, in the C6 cell of logarithmic growth phase5The cell suspension of a/mL is inoculated in 96 orifice plates,
Every 100 μ L of hole after culture for 24 hours, is handled, every group of 5 multiple holes according to following grouping:
Control group: it is changed to fresh culture and continues to cultivate 3h；
Aβ25-35Group (model group): it is changed to fresh culture and continues to cultivate 3h；
Doneppezil Hydrochloride group (positive drug group): it is changed to the fresh culture containing 20 μM of Doneppezil Hydrochlorides and continues to cultivate
3h；
New Zealand's Isoorientin group: it is changed to the fresh culture containing 5,10,20 μM of New Zealand's Isoorientins and continues to cultivate 3h.
Continue after cultivating 3h according to above-mentioned grouping, A β25-35Group, Doneppezil Hydrochloride group, the addition of New Zealand's Isoorientin group are eventually
The condensed state A β that concentration is 10 μM25-35, isometric solvent is added in control group, and after continuing culture 18h, 20 μ L MTT of each group addition are molten
Liquid (concentration 5mg/mL) continues at 37 DEG C to cultivate 4h.
Continue after cultivating 4h, careful inhale abandons supernatant in hole, and 150 μ L DMSO are added in every hole, shake 10min, fills crystallization
Divide dissolution；490nm wavelength is selected, each hole absorbance value (OD value) is measured on enzyme-linked immunosorbent assay instrument, takes 5 multiple holes OD values flat
Mean, calculates cell survival rate, and control group is denoted as 100%.
4, data processing and inversion
Using SPSS19.0 software, more comparison among groups are examined using one-way analysis of variance, are compared two-by-two between group and are examined using q
It tests.It is that difference is statistically significant with P < 0.05.
Three, experimental result
Group of cells survival rate (note: compared with the control group as shown in table 1#P < 0.05,##P < 0.01,###p<0.001；With A
β25-35Group compares * p < 0.05, p < 0.001 * * p < 0.01, * * *).
1. New Zealand's Isoorientin of table is to A β25-35The influence of the cellular damage of induction
Compared with the control group, A β25-35Group cell survival rate significantly reduces, and illustrates cell modeling success；With A β25-35Group phase
Than Doneppezil Hydrochloride group, New Zealand's Isoorientin group cell survival rate significantly increase.Doneppezil Hydrochloride is U.S.'s food and medicine
Object management board (FDA) approval for treating the drug of Alzheimer disease, 20 μM about make cell survival rate promote 4%, and 5 μM
New Zealand's Isoorientin just can make cell survival rate promote 5%, and as dosage increases protective effect enhancing, 10 μM can about promote 8%,
20 μM about make survival rate promote 14%, and have statistical difference.Cell Proliferation is promoted to cause in order to exclude New Zealand's Isoorientin
False positive, intervene influence of the lower New Zealand's Isoorientin to cell viability We conducted no A β and test, as a result such as 2 institute of table
Show, New Zealand's Isoorientin under 5,10,20 μM of concentration on cell viability without influence (P ﹥ 0.05), this is the result shows that New Zealand herds
Chaste tree glycosides does not cause cell Proliferation.
Influence of the 2. New Zealand's Isoorientin of table to C6 cell Proliferation vigor
Therefore, consolidated statement 1,2 results are believed that New Zealand's Isoorientin can protect neural cell injury caused by A β,
With exploitation at the prospect of anti senile dementia drug.
Claims (4)
1. application of New Zealand's Isoorientin in the drug of preparation prevention and treatment senile dementia.
2. application of the pharmaceutically acceptable salt of New Zealand's Isoorientin in the drug of preparation prevention and treatment senile dementia.
3. it is a kind of prevent and treat senile dementia pharmaceutical preparation, using New Zealand's Isoorientin or its pharmaceutically acceptable salt be drug work
Property ingredient, is made pharmaceutically acceptable preparation formulation.
4. pharmaceutical preparation according to claim 3, the preparation formulation is tablet, capsule, injection or oral solution.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910024767.0A CN109528746A (en) | 2019-01-10 | 2019-01-10 | Application of New Zealand's Isoorientin in the drug of preparation prevention and treatment senile dementia |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910024767.0A CN109528746A (en) | 2019-01-10 | 2019-01-10 | Application of New Zealand's Isoorientin in the drug of preparation prevention and treatment senile dementia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109528746A true CN109528746A (en) | 2019-03-29 |
Family
ID=65834964
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910024767.0A Pending CN109528746A (en) | 2019-01-10 | 2019-01-10 | Application of New Zealand's Isoorientin in the drug of preparation prevention and treatment senile dementia |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109528746A (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013079624A1 (en) * | 2011-11-29 | 2013-06-06 | Amino Up Chemical Co., Ltd. | Composition comprising vicenin-2 having a beneficial effect on neurological and/or cognitive function |
-
2019
- 2019-01-10 CN CN201910024767.0A patent/CN109528746A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013079624A1 (en) * | 2011-11-29 | 2013-06-06 | Amino Up Chemical Co., Ltd. | Composition comprising vicenin-2 having a beneficial effect on neurological and/or cognitive function |
Non-Patent Citations (1)
| Title |
|---|
| 耿丽颖: "《中国优秀硕士学位论文全文数据库（电子期刊）》", 31 May 2017 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4781771B2 (en) | Tomato extract for cancer treatment | |
| JP5394233B2 (en) | Evaluation method and screening method for substances having action to activate / inhibit innate immune mechanism, drug for activating / inhibiting innate immune mechanism, food, and production method thereof | |
| CN108721281A (en) | New antiviral drugs and its application | |
| KR101807953B1 (en) | The pharmaceutical composition for the prevention or treatment of the symptoms in the dementia comprising the extracts from Coriandrum sativum | |
| CN109528739A (en) | Application of the ilexin O in the drug of preparation prevention and treatment senile dementia | |
| CN109481487A (en) | Application of the taraxasterone in the drug of preparation prevention and treatment senile dementia | |
| CN110237074B (en) | Application of benidipine in preparation of medicine for preventing and/or treating bunidipine virus infectious diseases | |
| CN108310080A (en) | Application of the Black Box Tracing anthocyanin in preparing anti-hepatic fibrosis drug or health products | |
| Shcherbyna et al. | The research of 1, 2, 4-triazole derivatives hepatoprotective activity under tetracycline and infectious hepatitis | |
| CN109528746A (en) | Application of New Zealand's Isoorientin in the drug of preparation prevention and treatment senile dementia | |
| EP3162377B1 (en) | Dianxianning for preventing and treating alzheimer's disease | |
| CN106309455A (en) | Application of peimisine | |
| CN110433168B (en) | Application of cornuside in preparation of medicine for treating Alzheimer's disease | |
| Pattanayak et al. | Evaluation of anti-inflammatory activity of nyctanthes arbor-tristis leaves | |
| CN107468682A (en) | Application of the mangiferin in antiviral drugs is prepared | |
| CN110025612A (en) | Application of the Chrysin in preparation treatment methicillin-resistant staphylococcus aureus infectious pneumonia drug | |
| CN117137902B (en) | Application of (-) -equitable edible phenol in preparing medicine for preventing and/or treating Alzheimer disease | |
| CN109925326A (en) | Nematicidal fungi and anthelmintic combination formulations | |
| CN108186618A (en) | The new application of citral and its derivative in MRSA infectious disease medicaments are prepared | |
| KR102627493B1 (en) | Composition for preventing, improving or treating neurodegenerative disorders trimethyltin mediated comprising Ishige okamurae extract and uses thereof | |
| CN117180243B (en) | Use of carnosone in preparing medicine for preventing and/or treating Alzheimer disease | |
| KR20130046094A (en) | Medical composition comprising abutilon avicennae extract for preventing or treating inflammatory disease | |
| CN110801455B (en) | Pharmaceutical composition for treating MRSA and application thereof | |
| CN116370460A (en) | Application of aesculin in cryptococcus neoformans infectious diseases | |
| CN107982252B (en) | Application of traditional Chinese medicine composition in encephalitis B |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20190329 |